Mirati 012

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Trial overview

Topic

Mirati 012

Description

To compare the efficacy of MRTX849 versus docetaxel in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.

Physicians

Contact

East Coast-Jacksonville

Maddie Hamilton